What are the treatment options after acotinib/acalatinib resistance?

Acalabrutinib/Acalabrutinib is a second-generation BTK inhibitor for B-cell lymphoma. It has shown efficacy in the treatment of hematological malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Unfortunately, as treatment continues, some patients may develop resistance to acotinib. The development of this kind of drug resistance is often related to mutations in specific genes or other biological changes. Therefore, in-depth exploration of the resistance mechanism is particularly important for formulating next treatment plans for patients.

When patients develop resistance to acotinib, there are several possible treatment strategies. First, doctors may consider switching patients to other types of BTK inhibitors, such as ibrutinib or zanubrutinib. Since these drugs have different mechanisms of action and resistance characteristics from acotinib, they may provide new treatment opportunities for drug-resistant patients. It is worth noting that in most patients who develop drug resistance due to BTK gene mutations, these mutations can be detected months before clinical relapse. For these patients, the BCL2 inhibitor venetoclax may be an effective option, although its effects may only be short-lived.

In addition to dressing changes, combination therapy is also an option worth considering. By combining acotinib with other drugs, such as immunotherapy drugs, chemotherapy drugs or other targeted therapy drugs, it is possible to help patients overcome drug resistance, thereby further improving the effectiveness of treatment.

Additionally, participation in a clinical trial may be a good option for patients who no longer respond to traditional treatments. Clinical trials often explore cutting-edge treatments or drugs, providing new treatment opportunities for patients and potentially new ways to overcome drug resistance.